Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Health-related quality of life in patients with melanoma - characterization of a Swedish cohort.

Tufvesson Stiller H, Mikiver R, Uppugunduri S, Lindholm C, Månsson Brahme E, Schmitt-Egenolf M.

Br J Dermatol. 2019 Sep 5. doi: 10.1111/bjd.18486. [Epub ahead of print] No abstract available.

PMID:
31487398
2.

Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.

Norlin JM, Nilsson K, Persson U, Schmitt-Egenolf M.

Br J Dermatol. 2019 Jul 20. doi: 10.1111/bjd.18361. [Epub ahead of print]

PMID:
31325318
3.

What can we learn from 'dropouts' in clinical trials?

Schmitt-Egenolf M.

Br J Dermatol. 2018 Feb;178(2):318-319. doi: 10.1111/bjd.16220. No abstract available.

PMID:
29441540
4.

How is disease severity associated with quality of life in psoriasis patients? Evidence from a longitudinal population-based study in Sweden.

Geale K, Henriksson M, Schmitt-Egenolf M.

Health Qual Life Outcomes. 2017 Jul 28;15(1):151. doi: 10.1186/s12955-017-0721-x.

5.
6.

Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients.

Hägg D, Sundström A, Eriksson M, Schmitt-Egenolf M.

Am J Clin Dermatol. 2017 Aug;18(4):583-590. doi: 10.1007/s40257-017-0274-0.

7.

Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy.

Norlin JM, Calara PS, Persson U, Schmitt-Egenolf M.

J Dermatolog Treat. 2017 Sep;28(6):500-504. doi: 10.1080/09546634.2017.1289147. Epub 2017 Mar 2.

PMID:
28132580
8.

Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 Patients.

Calara PS, Althin R, Carlsson KS, Schmitt-Egenolf M.

BioDrugs. 2017 Feb;31(1):75-82. doi: 10.1007/s40259-016-0209-y.

9.

Periodontal Ehlers-Danlos Syndrome Is Caused by Mutations in C1R and C1S, which Encode Subcomponents C1r and C1s of Complement.

Kapferer-Seebacher I, Pepin M, Werner R, Aitman TJ, Nordgren A, Stoiber H, Thielens N, Gaboriaud C, Amberger A, Schossig A, Gruber R, Giunta C, Bamshad M, Björck E, Chen C, Chitayat D, Dorschner M, Schmitt-Egenolf M, Hale CJ, Hanna D, Hennies HC, Heiss-Kisielewsky I, Lindstrand A, Lundberg P, Mitchell AL, Nickerson DA, Reinstein E, Rohrbach M, Romani N, Schmuth M, Silver R, Taylan F, Vandersteen A, Vandrovcova J, Weerakkody R, Yang M, Pope FM; Molecular Basis of Periodontal EDS Consortium, Byers PH, Zschocke J.

Am J Hum Genet. 2016 Nov 3;99(5):1005-1014. doi: 10.1016/j.ajhg.2016.08.019. Epub 2016 Oct 13.

10.

Physical activity and lifestyle improvement in the management of psoriasis.

Schmitt-Egenolf M.

Br J Dermatol. 2016 Sep;175(3):452-3. doi: 10.1111/bjd.14899. No abstract available.

PMID:
27632957
11.

Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice.

Calara PS, Norlin JM, Althin R, Carlsson KS, Schmitt-Egenolf M.

BioDrugs. 2016 Apr;30(2):145-51. doi: 10.1007/s40259-016-0163-8.

PMID:
26883786
12.

Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.

Norlin JM, Carlsson KS, Persson U, Schmitt-Egenolf M.

BioDrugs. 2015 Dec;29(6):389-98. doi: 10.1007/s40259-015-0151-4.

PMID:
26670179
13.

Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription of biologics.

Geale K, Henriksson M, Schmitt-Egenolf M.

Br J Dermatol. 2016 Mar;174(3):579-87. doi: 10.1111/bjd.14331. Epub 2016 Feb 4.

PMID:
26616003
14.

Hair shaft structures in EDAR induced ectodermal dysplasia.

Stecksén-Blicks C, Falk Kieri C, Hägg D, Schmitt-Egenolf M.

BMC Med Genet. 2015 Sep 4;16:79. doi: 10.1186/s12881-015-0227-5.

15.

Real-world outcome analysis of continuously and intermittently treated patients with moderate to severe psoriasis after switching to a biologic agent.

Hjalte F, Steen Carlsson K, Schmitt-Egenolf M.

Dermatology. 2015;230(4):347-53. doi: 10.1159/000371881. Epub 2015 Feb 20.

PMID:
25721571
16.

[Register studies measure the effectiveness of drugs in clinical practice. The example PsoReg - redistribution of systemic treatment can increase the efficiency].

Norlin J, Schmitt-Egenolf M, Carlsson KS, Persson U.

Lakartidningen. 2014 Jun 11-17;111(24):1061-3. Swedish. No abstract available.

17.

Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI).

Hägg D, Sundström A, Eriksson M, Schmitt-Egenolf M.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):452-6. doi: 10.1111/jdv.12576. Epub 2014 Jun 9.

PMID:
24911993
18.

EDAR-induced hypohidrotic ectodermal dysplasia: a clinical study on signs and symptoms in individuals with a heterozygous c.1072C > T mutation.

Kieri CF, Bergendal B, Lind LK, Schmitt-Egenolf M, Stecksén-Blicks C.

BMC Med Genet. 2014 May 16;15:57. doi: 10.1186/1471-2350-15-57.

19.

Resource use in patients with psoriasis after the introduction of biologics in Sweden.

Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M.

Acta Derm Venereol. 2015 Feb;95(2):156-61. doi: 10.2340/00015555-1895.

20.

Health-care delay in malignant melanoma: various pathways to diagnosis and treatment.

Hajdarevic S, Hörnsten A, Sundbom E, Isaksson U, Schmitt-Egenolf M.

Dermatol Res Pract. 2014;2014:294287. doi: 10.1155/2014/294287. Epub 2014 Jan 5.

Supplemental Content

Loading ...
Support Center